| Outcome Measures: |
Primary: Evolution of Glycated hemoglobin (HbA1c) level, weight and the onset of hypoglycemic over time (2 years) for patients treated with Saxagliptin, HbA1c level \<7% at Y2, weight and assessment of hypoglycaemic events after a 2-year exposure to Saxagliptin, 24 months|Joint population of Saxagliptin based on socio-demographic data, medical history, disease history, comorbidities including renal, hepatic and cardiac functions, HbA1c level at treatment initiation), One year (average)|Utilization of Saxagliptin by General practitioners (GPs) and diabetologists in France (based on indication, initial dosage and adjustments, co-prescriptions, glycemic monitoring), During the treatment (Up to 2 years)|Retention rate of Saxagliptin and to describe discontinuation rate and reasons, At 2 years | Secondary: Distribution of different hypoglycaemic therapeutic strategies used in France and characteristics of T2D patients depending on therapeutic strategies, 2 month|Saxagliptin utilization according to patient's profile and disease characteristics, 24 month
|
